Appendix 4E and Annual Report 2022
Filed with ASX · · 76 pages · English
14. COMMENTARY OF RESULTS: Commentary in respect of the financial results is provided in the Review of Operations and Financial Condition in the attached Annual Report. DIVERSIFICATION Diversifying towards a sustainable pharmaceutical group. Balancing growth and expansion in a challenging operating environment. The approval of SCENESSE® (afamelanotide 16mg) for the prevention of phototoxicity in a
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- Positive Final Results in Stroke Study CUV801
- ACTH Manufacturing Update
- afamelanotide in Stroke (AIS) - Positive Preliminary Results
- CLINUVEL Reports December Half Year Operating Results
- Appendix 4D Half Year Report
Later from Clinuvel Pharmaceuticals
- S&P DJI Announces September 2022 Quarterly Rebalance
- Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4E and Annual Report to Shareholders 2023
- CUV Appendix 4D Half Year Report
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals